Organon is a global women’s healthcare company that announced the completion of its acquisition of Alydia Health. A commercial-stage medical device company focused on preventing postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding, which causes maternal morbidity and mortality.Postpartum hemorrhage is one of the most common delivery complications, needing pharmacologic therapy in up to 10% of moms and potentially necessitating emergency procedures, including hysterectomy and blood transfusions. In addition, PPH can cause maternal death in the worst-case scenario. PPH claimed the lives of 40,510 women worldwide in 2016.
Kevin Ali, CEO of Organon, said, “Organon acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women’s unmet medical needs. This acquisition brings us one step closer to our vision of a better and healthier every day for every woman around the world.”
In March 2021, Organon agreed to buy Alydia Health. Merck, which also known as MSD outside the United States and Canada, paid $50 million at signing in March 2021, and Organon paid $165 million at closing, for a total consideration of $240 million, which included a $215 million cash payment and a $25 million contingent milestone payment.